This ensures researchers can study GLP-1 therapies in populations that reflect real-world diversity, accounting for variations in age, ethnicity, socioeconomic status, and comorbid conditions
Your healthcare provider should guide your specific dosing decisions
Clinical trials have demonstrated that patients can achieve significant weight reductions, often exceeding 10-15% of their body weight over a 68-week period
ABIN651691 Quick Overview for GLP-1 antibody (AA 85-112) (ABIN651691) Target See all GLP-1 Antibodies Reactivity Host Clonality Conjugate Application Clone Binding Specificity AA 85-112 Purification This antibody is purified through a protein A column, followed by peptide affinity purification
Compound synthesis and formulation The different GLP1-based multi-agonists employed in the study, including GLP1/E, GLP1/GIP dual agonist, and GLP1/GIP/glucagon triagonist, as well as the GLP1 mono-agonist, were synthesized, purified and characterized as extensively reported elsewhere 33,34,35,74